German Start-up revolutionizes industrial 3D printing

After starting series production in the spring of 2019, the company AIM3D GmbH from Rostock draws a positive conclusion. “Our product has generated great interest in the industry with its novel CEM process and we have received numerous requests.” summarizes CSO Mr. Daniel Selck. “From now on we are searching for business partner and reseller Read more about German Start-up revolutionizes industrial 3D printing[…]

AIM3D sets new impulses by starting series production of its unique CEM 3D-printer.

After just two years of development and thanks to the productive and close cooperation with beta-customers, AIM3D GmbH can starts the series production of its unique 3D printer which is able to process injection moulding granulate. Just in time for the Rapid.Tech + FabCon3.D 2019 in Erfurt, the exhibition where exactly two years ago the Read more about AIM3D sets new impulses by starting series production of its unique CEM 3D-printer.[…]

thyssenkrupp Plastics GmbH celebrates tenth anniversary in Germany

The new thyssenkrupp Plastics GmbH started operations on October 1, 2009. Today marks the tenth anniversary of the successful combination of thyssenkrupp’s plastics activities in one company. "We are proud that together we have already been a successful market player for a decade, constantly developing in collaboration with our customers and suppliers. We will continue Read more about thyssenkrupp Plastics GmbH celebrates tenth anniversary in Germany[…]

Immungenetics AG: Last Patient Last Visit (LPLV) reached in first part of the DrainAD Study, a Phase 2 trial for the early diagnosis and causative treatment of Alzheimer’s Disease (AD)

Immungenetics AG, a German based biopharmaceutical company focusing on novel treatments for unmet medical needs in the field of neurodegenerative, autoimmune diseases and aging, announced today that the last study visit of the last patient enrolled (Last Patient’s Last Visit, LPLV) occurred on 06 June 2018 in the first subgroup of DrainAD, a Phase II proof-of-concept study Read more about Immungenetics AG: Last Patient Last Visit (LPLV) reached in first part of the DrainAD Study, a Phase 2 trial for the early diagnosis and causative treatment of Alzheimer’s Disease (AD)[…]